Aratana Therapeutics Inc
Change company Symbol lookup
Select an option...
PETX Aratana Therapeutics Inc
CIG Companhia Energetica de Minas Gerais CEMIG
GBBFF Granada Gold Mine Inc
SPTM SPDR® Portfolio Total Stock Market ETF
LMTI Laser Master International Inc
IPIX Innovation Pharmaceuticals Inc
PFF iShares Preferred and Income Securities ETF
BAC Bank of America Corp
INB Cohen & Steers Global Income Builder Inc
MSSZF Massimo Zanetti Beverage Group SpA
Go

Health Care : Pharmaceuticals | Small Cap GrowthCompany profile

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Closing Price
$4.78
Day's Change
-0.09 (-1.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.88
Day's Low
4.77
Volume
(Light)
Volume:
249,784

10-day average volume:
422,612
249,784
  • Prev Close
    4.87
  • Today's Open
    4.85
  • Day's Range
    4.77-4.88
  • Avg Vol (10-day)
    422.6K
  • Last (time)
    4:00p ET 06/14/19
  • Last (size)
    16.8K
  • 52-Wk Range
    3.30 - 7.16
    LowHigh
  • (11/08/18 - 03/13/19)
    44.85%
  • 60.9%
  • Market Cap
    234.1M
  • Shares Outstanding
    49.0M
  • -0.27
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.4
  • 60.18
  • (% of float 05/31/19)
    1.23

Latest News

June 11, 2019
4:05 pm ET
PR Newswire
June 07, 2019
4:59 pm ET
PR Newswire
3:37 pm ET
Globe Newswire
June 06, 2019
6:27 pm ET
Globe Newswire
3:20 pm ET
Globe Newswire
2:36 pm ET
Globe Newswire
May 13, 2019
5:19 pm ET
PR Newswire
May 09, 2019
2:24 pm ET
Globe Newswire
May 08, 2019
4:05 pm ET
PR Newswire
May 07, 2019
8:00 am ET
PR Newswire
April 30, 2019
2:17 pm ET
Globe Newswire
April 29, 2019
5:28 pm ET
Globe Newswire
10:10 am ET
Globe Newswire
9:31 am ET
PR Newswire
April 26, 2019
8:25 pm ET
Globe Newswire
5:37 pm ET
Globe Newswire
2:25 pm ET
PR Newswire
7:55 am ET
MarketWatch
6:29 am ET
BusinessWire
6:28 am ET
PR Newswire
April 22, 2019
8:30 am ET
PR Newswire
April 01, 2019
7:24 am ET
Globe Newswire
January 11, 2019
8:50 am ET
MarketWatch
8:35 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.